Minerva Neurosciences, Inc. — 2017 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2017. The filing is an annual report, not a standalone Q4 filing; quarterly Q4 figures are included where available.
Business context
Minerva is a clinical-stage biopharmaceutical company developing CNS treatments. It had no approved products and no product-sales revenue. Its pipeline comprised roluperidone (schizophrenia), seltorexant (insomnia and adjunctive treatment for major depressive disorder, co-developed with Janssen), MIN-117 (major depressive disorder), and preclinical MIN-301 (Parkinson’s disease).
Key financial metrics
| Metric | FY 2017 | FY 2016 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $30.3 million | $20.4 million |
| General and administrative expense | $10.9 million | $9.8 million |
| Total operating expenses / operating loss | $41.2 million | $30.2 million |
| Net loss | $31.5 million | $31.0 million |
| Basic and diluted loss per share | $0.83 | $0.99 |
| Operating cash flow | $3.1 million provided | $25.7 million used |
| Cash, cash equivalents and marketable securities | $133.2 million | $83.0 million |
| Notes payable, including current portion | $4.0 million | $8.7 million |
Margins are not meaningful because the company reported no revenue. The 2017 operating cash inflow was primarily driven by $41.2 million in deferred revenue associated with the Janssen amendment; it should not be read as evidence of recurring operating cash generation.
At year-end, current assets were $129.5 million and current liabilities were $6.8 million. Total liabilities were $52.1 million, including $41.2 million deferred revenue and $4.0 million notes payable. Cash and cash equivalents alone were $26.1 million; marketable securities totaled $107.1 million. Management said available cash, equivalents and securities should cover commitments for at least 12 months after issuance of the financial statements.
Q4 2017 revenue was $0; operating loss was $9.5 million. The quarter reported net income of $162,000 and basic and diluted EPS of $0.00, following losses in the first three quarters. The annual $9.4 million income-tax benefit was a noncash tax-accounting item related to the 2017 tax law changes, not operating earnings.
Material changes versus the prior year
- R&D expense increased $9.8 million, principally due to seltorexant Phase 2 work, increased roluperidone development, personnel and stock-based compensation; MIN-117 costs declined after completion of its Phase 2a trial.
- Net loss increased modestly, while loss per share improved from $0.99 to $0.83, reflecting a higher weighted-average share count.
- Cash and marketable securities increased by $50.2 million. Funding included a July 2017 stock offering that generated $41.6 million net, $9.4 million from warrant exercises and a $30 million Janssen upfront payment.
- Debt fell from $8.7 million to $4.0 million after principal repayments. Approximately $3.5 million of Term A principal was expected to be repaid in 2018; the loan matured August 1, 2018.
Outlook, management commentary and risks
- Roluperidone’s pivotal Phase 3 trial began screening its first patient in December 2017. The study planned approximately 500 participants; top-line results for the 12-week blinded phase were expected in the first half of 2019. The prior Phase 2b trial met its primary endpoint, but Phase 3 efficacy and safety remained unproven.
- Three Phase 2b seltorexant studies began enrolling in 2017: two in adjunctive MDD and one in insomnia. Under the amended Janssen agreement, Minerva assumed strategic control of insomnia development and has no further financial obligations until the Phase 2b milestone, expected in the second half of 2019. If it proceeds to Phase 3, it would fund insomnia trials and 40% of Janssen’s Phase 3 MDD development costs; Janssen committed $40 million in insomnia milestones.
- Minerva planned to begin a U.S. and European Phase 2b trial of MIN-117 in early 2018. MIN-301 remained in preclinical development, with a Phase 1 study expected after preparation for an IND or equivalent filing.
- The Janssen amendment provided a $30 million upfront payment and forgiveness of $11.2 million in previously accrued collaborative expenses. Both amounts were recorded in deferred revenue and were to be recognized as services were performed beginning with Phase 3 development. The filing therefore reports no 2017 revenue despite the upfront payment.
- Management expected continued losses and negative operating cash flow as development progressed and stated that additional capital would be needed to fund operations and later-stage trials. Future financing may dilute shareholders or may not be available on acceptable terms.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, dependence on Janssen, MTPC and other third parties, manufacturing and enrollment risks, competition, intellectual-property limits, reimbursement and pricing pressure, and the possibility of impairment of in-process R&D or goodwill. Roluperidone and MIN-117 had prior safety observations that included possible QT/QTc effects.
- The audited financial statements received an unqualified audit opinion. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not provide an internal-controls attestation because Minerva was an emerging growth company. No material legal proceedings were reported.
Important facts for investors to verify
- Clinical-trial enrollment, timelines, endpoints and subsequent results—especially roluperidone Phase 3 and the seltorexant Phase 2b programs.
- Cash burn and runway, including how the Janssen deferred revenue is recognized and how cash commitments change as trials advance.
- Janssen agreement terms at Decision Point 4, including the option to opt out, potential royalties and the costs of continuing into Phase 3.
- 2017 tax benefit and deferred-tax balances, including the assumptions underlying the $9.4 million benefit and the potential Section 382 limits on NOL use.
- Debt repayment and covenant status, plus the effects of future equity issuance and stock-based compensation on dilution.